Trial Profile
Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Nov 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Nanology
- 07 Nov 2023 Status changed from active, no longer recruiting to completed.
- 10 Oct 2023 According to a NanOlogy media release, two posters presented downstaging and immune data from this study were presented at ninth AACR Special Conference on Pancreatic Cancer.
- 10 Oct 2023 According to a NanOlogy media release, the research article reports data from evaluable subjects in the first two cohorts while the third is pending final readout.